AbbVie: Skyrizi Phase 3 Crohn's Induction Studies Meet Main Endpoints
By Colin Kellaher
AbbVie Inc. on Thursday said a pair of Phase 3 induction studies
of its psoriasis treatment Skyrizi met both primary endpoints in
patients with Crohn's disease, a chronic inflammatory bowel
The North Chicago, Ill., biopharmaceutical company said a
significantly greater proportion of patients treated with either a
600-milligram or 1,200-milligram dose of Skyrizi showed
statistically significant results for clinical remission and
endoscopic response at week 12 compared to placebo.
The company also noted that the overall safety results in the
studies were generally consistent with the known safety profile of
the drug, with no new risks observed. AbbVie added that a
maintenance study for Crohn's disease is continuing.
AbbVie earlier this week reported positive top-line results from
two Phase 3 studies of Skyrizi in adults with active psoriatic
The drug, which received U.S. and European approval in 2019 for
adults with moderate to severe plaque psoriasis, is part of a
collaboration between AbbVie and German pharmaceutical company
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
January 07, 2021 09:41 ET (14:41 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.